These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 12698397

  • 1. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
    Koster A, Fischer T, Gruendel M, Mappes A, Kuebler WM, Bauer M, Kuppe H.
    J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
    [Abstract] [Full Text] [Related]

  • 2. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons.
    Rao AK, Sun L, Hiramatsu Y, Gorman JH, Edmunds LH.
    Thromb Haemost; 1999 Jul; 82(1):140-4. PubMed ID: 10456468
    [Abstract] [Full Text] [Related]

  • 3. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ, Joist JH.
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [Abstract] [Full Text] [Related]

  • 4. Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade.
    Durand M, Lecompte T, Hacquard M, Carteaux JP.
    Eur J Cardiothorac Surg; 2008 Sep; 34(3):687-9. PubMed ID: 18579401
    [Abstract] [Full Text] [Related]

  • 5. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
    Koster A, Fischer T, Praus M, Haberzettl H, Kuebler WM, Hetzer R, Kuppe H.
    Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
    [Abstract] [Full Text] [Related]

  • 6. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, Watanabe N.
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
    Chomiak PN, Walenga JM, Koza MJ, Reilly TM, Turlapathy P, Pifarre R.
    Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
    [Abstract] [Full Text] [Related]

  • 10. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass.
    Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS.
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):47-52. PubMed ID: 18249330
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ, Velan T, Aldea GS, Chandler WL.
    Thromb Res; 2006 Feb; 117(6):689-703. PubMed ID: 15996721
    [Abstract] [Full Text] [Related]

  • 13. r-Hirudin inhibits platelet-dependent thrombosis during cardiopulmonary bypass in baboons.
    van Wyk V, Neethling WM, Badenhorst PN, Kotzé HF.
    J Cardiovasc Surg (Torino); 1998 Oct; 39(5):633-9. PubMed ID: 9833724
    [Abstract] [Full Text] [Related]

  • 14. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
    Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, Loebe M, Hetzer R, Kuppe H.
    Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
    [Abstract] [Full Text] [Related]

  • 15. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children.
    Eisses MJ, Geiduschek JM, Jonmarker C, Cohen GA, Chandler WL.
    J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):28-34. PubMed ID: 17289476
    [Abstract] [Full Text] [Related]

  • 16. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response.
    Koster A, Huebler S, Merkle F, Hentschel T, Gründel M, Krabatsch T, Tambeur L, Praus M, Habazettl H, Kuebler WM, Kuppe H.
    Anesth Analg; 2004 Feb; 98(2):285-290. PubMed ID: 14742356
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
    Tabata S, Yamaguchi S, Nagamine H, Tomita S, Arai S, Takemura H, Watanabe G.
    Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.